Skip to content

Using interferon to treat COVID-19

Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161206031256N3
Enrollment
76
Registered
2020-06-02
Start date
2020-05-23
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. the code for the confirmed diagnosis of COVID-19

Interventions

Intervention 1: Intervention group 1: patients who will receive standard care plus 4 consecutive doses of intramuscular injection of beta-interferon (each vial contains 30 micrograms of interferon equ

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor
CinnaGen company
Collaborator
Pooyesh Darou company
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult over 18 years Clinical diagnosis of COVID-19

Exclusion criteria

Exclusion criteria: History of allergy to human albumin or interferon

Design outcomes

Primary

MeasureTime frame
Body temperature. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Thermometer, Celsius.;Respiratory rate. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Pulse oximeter, Breaths per minute.;The ratio of arterial oxygen partial pressure to fractional inspired oxygen. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Ventilator, Millimeter of mercury (mmHg).;Blood gas level. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Blood Gas Analyzer, percent.

Secondary

MeasureTime frame
Lymphocyte count. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Cell counter, Cell per milliliter.;Lymphocyte count. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Cell counter, Cell per milliliter.;C-reactive protein level. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Clinical Biochemistry Analyzer, milligram per deciliter.;Erythrocyte Sedimentation Rate. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: ESR analyzer, millimeter per hour.;Alanine aminotransferase Level. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Autoanalyzer, Unit per liter.;Aspartate aminotransferase Level. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Autoanalyzer, Unit per liter.;Total/ conjugated bilirubin levels. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Autoanalyzer, Milligram per deciliter.;Creatinine. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Autoanalyzer, Milligram per deciliter.;Creatine kinase myocardial band (CK-MB). Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: Autoanalyzer, international unit per liter.;Troponin. Timepoint: Before intervention, on day of 1 until discharge, with 3 day interval. Method of measurement: enzyme-linked immunosorbent assay, nanogram per mililitere.;Hospitalization time. Timepoint: Admission time until discharge. Method of measurement: ?Day.;Mortality rate. Timepoint: on day of 14 and 28 after intervention. Method of measurement: Mortality formula.;National early warning score 2. Timepoint: On day of 1 and 7 after intervention. Met

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmaryam Khoshkhui

Mashhad University of Medical Sciences

b.ghaem@mums.ac.ir+98 51 3840 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026